reports
WINFARM : Implantation d'Alphatech à Singapour pour répondre à la fort...
WINFARM : Implantation d'Alphatech à Singapour pour répondre à la forte hausse de la demande sur la zone APAC. COMMUNIQUE DE PRESSE Loudéac, 15 avril 2025 IMPLANTATION D’ALPHATECH A SINGAPOUR POUR REPONDRE A LA FORTE HAUSSE DE LA DEMANDE SUR LA ZONE APAC WINFARM (code ISIN : FR0014000P11 - mnémonique : ALWF), n°1 français de la vente à distance pour le monde agricole, annonce l’ouverture de sa filiale Alphatech APAC à Singapour. Cette implantation, va permettre à la Société de mieux répondre à l’explosion de la demande sur cette zone stratégique à très fort potentiel. Avec cette nouv...
Pharming Group announces the filing of its 2024 Annual Report and Form...
Pharming Group announces the filing of its 2024 Annual Report and Form 20-F Leiden, the Netherlands, April 3, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM / Nasdaq: PHAR) announces the filing of its Annual Report for the year ended December 31, 2024 (the “Period”). The Annual Report is available under Investors/Financial documents on the Pharming.com website. The Company also announces the filing of its Annual Report on Form 20-F with the U.S. Securities and Exchange Commission (SEC) for the Period. The 2024 Annual Report on Form 20-F can be found und...
WINFARM : 2024 full-year results and 2025 outlook.
WINFARM : 2024 full-year results and 2025 outlook. PRESS RELEASE Loudéac, 31 March 2025 2024 FULL-YEAR RESULTS Significant improvement in H2 2024 on revenue and EBITDA, in line with targets Solid annual gross margin and positive operating profitability in 2024despite a difficult environment 2025 OUTLOOK Build on H2 2024 momentum to pursue revenue growth Rigorous financial discipline to improve EBITDA Continue reduction of Group debt WINFARM (ISIN: FR0014000P11 - ticker: ALWF), the number one French distance seller for the farming industry, today release its consolidated 2024 ful...
WINFARM : Résultats annuels 2024 et perspectives 2025.
WINFARM : Résultats annuels 2024 et perspectives 2025. COMMUNIQUE DE PRESSE Loudéac, 31 mars 2025 RESULTATS ANNUELS 2024 Deuxième semestre 2024 en nette amélioration en termes de chiffre d’affaires et d’EBITDA conformément aux objectifs fixés Bonne tenue de la marge brute annuelle et rentabilité opérationnelle positive en 2024malgré un contexte difficile PERSPECTIVES 2025 Capitaliser sur la dynamique du 2ème semestre pour poursuivre une croissance du chiffre d’affaires Discipline financière stricte favorisant l’amélioration de l’EBITDA Poursuite du désendettement du Groupe WINFA...
- Michael B. Schäfer
- Michael B. Schäfer
- Christophe Chaput
- Christophe Chaput
Pharming Group announces first patient dosed in Phase II clinical tria...
Pharming Group announces first patient dosed in Phase II clinical trial of leniolisib for common variable immunodeficiency (CVID) with immune dysregulation Multi-center clinical trial includes sites located in the US, UK and EU Second Phase II clinical trial studying leniolisib for additional primary immunodeficiencies (PIDs) CVID patients demonstrate clinical phenotypes similar to APDS, with global prevalence estimated at approximately 39 per million Leiden, the Netherlands, March 20, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) an...
Pharming Group reports fourth quarter and full year 2024 financial res...
Pharming Group reports fourth quarter and full year 2024 financial results and provides business update Full year 2024 total revenues increased by 21% to US$297.2 million and exceeded our guidance, driven by record RUCONEST® revenue and strong Joenja® (leniolisib) growth Fourth quarter 2024 total revenues increased by 14% to US$92.7 million, compared to the fourth quarter 2023RUCONEST® full year revenue increased by 11% to US$252.2 million and fourth quarter revenue increased by 9% to US$79.6 million, compared to the fourth quarter 2023Joenja® revenue increased by 147% to US$45.0 million in...
Pharming Group reports on results of the 2025 Extraordinary General Me...
Pharming Group reports on results of the 2025 Extraordinary General Meeting of Shareholders Leiden, the Netherlands, March 4, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces today that the Extraordinary General Meeting of Shareholders (EGM) has adopted all proposals on the EGM agenda. Shareholders approved the appointment of Mr. Fabrice Chouraqui as Executive Director and Chief Executive Officer for a term of four years. As a result, Mr. Chouraqui succeeds Mr. Sijmen de Vries with immediate effect. To ensure a smooth hand-over of...
Pharming Group to participate in March investor conference
Pharming Group to participate in March investor conference Leiden, the Netherlands, February 28, 2025: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming’s management will participate in the following investor conference in the month of March: 37th Annual Roth Conference, Dana Point, CA, USA, March 16-18, 2025Anurag Relan, Chief Medical Officer, and Michael Levitan, VP Investor Relations and Corporate Communications, will participate in a fireside chat question and answer session on Monday, March 17 at 01:30pm PT/21:30 CET. For more informati...
Pharming Group to report fourth quarter and full year 2024 financial r...
Pharming Group to report fourth quarter and full year 2024 financial results on March 13 Leiden, the Netherlands, February 27, 2025: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms it will report its preliminary (unaudited) fourth quarter and full year 2024 financial results, for the period ended December 31, on Thursday, March 13, 2025. Pharming will host a presentation for analysts and investors at 13:30 CET/08:30 am EDT on March 13, 2025. To participate in the conference call, please register in advance using the link below. Once registered, dial-in...
Pharming Technologies B.V. increases its ownership in Abliva AB (publ)...
Pharming Technologies B.V. increases its ownership in Abliva AB (publ) to 92.70 percent This press release is not an offer, whether directly or indirectly, in Australia, Canada, Hong Kong, Japan, New Zealand or South Africa or in any other jurisdiction where such offer pursuant to legislation and regulations in such relevant jurisdiction would be prohibited by applicable law. Shareholders not resident in Sweden who wish to accept the Offer (as defined below) must make inquiries concerning applicable legislation and possible tax consequences. Shareholders should refer to the offer restrictio...
- Baptiste Salaville
- Charlotte Vaisse
- Gautier Le Bihan
- Baptiste Salaville
- Charlotte Vaisse
- Gautier Le Bihan
- Christophe Chaput
- Christophe Chaput
Pharming Group to participate in February investor conference
Pharming Group to participate in February investor conference Leiden, the Netherlands, February 10, 2025: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming’s management will participate in the following investor conference in the month of February: Oppenheimer 35th Annual Healthcare Life Sciences Conference, Virtual, February 11-12, 2025Sijmen de Vries, Chief Executive Officer and Anurag Relan, Chief Medical Officer, will present on Wednesday, February 12 at 08:40 ET/14:40 CET. A live webcast and replay of the presentation will be available i...
Pharming Technologies B.V. declares unconditional and completes the re...
Pharming Technologies B.V. declares unconditional and completes the recommended cash offer to the shareholders of Abliva AB (publ) and extends the acceptance period This press release is not an offer, whether directly or indirectly, in Australia, Canada, Hong Kong, Japan, New Zealand or South Africa or in any other jurisdiction where such offer pursuant to legislation and regulations in such relevant jurisdiction would be prohibited by applicable law. Shareholders not resident in Sweden who wish to accept the Offer (as defined below) must make inquiries concerning applicable legislation and...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.